PA Capital’s Tempest Therapeutics TPST Stock Holding History

PA Capital’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-78	Closed	-$229K	–	117
2019 Q1	$229K	Buy	78 +6	+8%	+$13.3K	0.2%	101
2018 Q4	$111K	Buy	+72	New	+$148K	0.12%	105

Other funds holding TPST

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PA Capital's TPST Position: Q2 2019 in Review

PA Capital sold out of Tempest Therapeutics (TPST) in Q2 2019, closing a stake of 78 shares — an estimated $229K sold.

PA Capital first reported a position in TPST in Q4 2018 and held it in 2 quarters. The position peaked at $229K in Q1 2019. 38 funds tracked by Wall St. Rank hold TPST as of Q2 2019.

PA Capital reported no remaining Tempest Therapeutics position as of Q2 2019 after selling out during the quarter.
PA Capital sold 78 Tempest Therapeutics shares in Q2 2019, an estimated $229K.
PA Capital first reported a position in Tempest Therapeutics in Q4 2018 and held it in 2 quarters.
PA Capital's Tempest Therapeutics position peaked at $229K in Q1 2019.
38 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2019.

Based on PA Capital's 13F filing for Q2 2019, filed 8 Aug 2019.